美国FDA认为全谷物与二型糖尿病风险降低之间的关系不显著

    食品伙伴网讯 据国外食品类网站消息，2012年康尼格拉食品公司向美国FDA提交申请，FDA发表结论认为，非常有限的科学证据会支持全谷物与降低二型糖尿病风险之间的关系，因此拟限制性批准该健康声称，以避免误导消费者。

    康尼格拉食品公司表示，虽然对FDA的评定有些失望，但是仍认为此举具有里程碑意义，并表示不会重新提交申请书。

    Qualified health claims enable firms to talk about a relationship between a substance and disease where the supporting science fails to meet the FDA's 'significant scientific agreement' standard, but the claims are 'qualified' in such a way as to not mislead consumers.

    While the qualification often comes in the form of a far-from-consumer-friendly disclaimer, many observers believe the claims are still better than nothing.

    As a result, the FDA will consider exercising its enforcement discretion for the following qualified health claims:

    'Whole grains may reduce the risk of type 2 diabetes, although the FDA has concluded that there is very limited scientific evidence for this claim.'

    OR: 'Whole grains may reduce the risk of type 2 diabetes. FDA has concluded that there is very limited scientific evidence for this claim.'

    In its petition, ConAgra had suggested the following wording: 'Scientific evidence suggests, but does not prove, that diets low in saturated fat and cholesterol that include three servings （48g） of whole grains per day may reduce the risk of diabetes mellitus type 2.'

    原文链接：<http://www.foodnavigator-usa.com/Regulation/FDA-permits-qualified-health-claim-about-whole-grains-and-type-2-diabetes-but-is-the-wording-so-qualified-no-one-will-use-it>